How the AAD System Works

The I-neb AAD System uses Adaptive Aerosol Delivery (AAD) technology to precisely and reproducibly deliver Ventavis® (iloprost) Inhalation Solution to every patient, at either dose (2.5 mcg or 5.0 mcg), using a single ampule of medication. The I-neb AAD System monitors a patient's unique breathing pattern and adapts to breathing changes during treatment. The I-neb AAD System delivers Ventavis in the form of a mist only upon inhalation. This is the time when the body can best absorb the medication.

With the I-neb AAD System, a medication chamber controls the dose and a control disc operates the I-neb AAD System. Once a patient receives a complete dose, the I-neb AAD System stops delivering aerosol and signals the user with visual and audible indicators.

Maximum lung deposition2,22

I-neb AAD analyzes breathing patterns for precision dosing

  • Determines starting point for aerosol delivery by measuring pressure changes in airflow2
  • Sets duration of each pulse by analyzing breathing pattern2
  • Continually adapts aerosol delivery to changes in breathing patterns2,22
  • Less aerosol waste with I-neb AAD as compared with conventional nebulizers2

I-neb AAD: Breath actuated precision dosing analyzes breathing patterns

Adapted from Nikander22Based on an in vitro study.

I-neb generates micro-aerosol and analyzes breathing patterns, delivering the drug during only the first 80% of inhalation to maximize lung deposition.2,22

Indication and Important Safety Information

OPEN CLOSE

Indication:

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

Important Safety Information

  • Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg.
  • Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.
  • Ventavis inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive.
  • Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis.
  • In clinical studies, the most common adverse events occurring more often (≥6%) in Ventavis-treated patients than in patients taking placebo included vasodilation (flushing) (27% vs 9%), cough (39% vs 26%), headache (30% vs 20%), trismus (12% vs 3%), and insomnia (8% vs 2%).
  • Ventavis has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
  • Ventavis also has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information.